疑似冠心病初始负荷试验与解剖试验后的生存率:PROMISE随机临床试验长期随访
结果显示两组全因死亡率无显著差异(HR 0.98;95%CI 0.87-1.10),心血管死亡点估计偏向CTA但无统计学差异(HR 0.84;95%CI 0.67-1.05)。
要点
- 初始CTA与负荷试验在10年全因死亡和心血管死亡上无显著差异。
- CTA提示任何程度异常(含轻度非阻塞性)均与死亡风险升高相关。
- 负荷试验仅严重异常具有预后意义。
核心结论
- 在疑似冠心病稳定症状患者中,初始无创检查选择(CTA或负荷试验)未影响10年全因或心血管死亡率。
主要发现
- 全因死亡1128例(14.4%),CTA组558例(14.3%),负荷试验组570例(14.5%),未调整HR 0.98(95%CI 0.87-1.10)。
- 心血管死亡无显著差异,点估计偏向CTA(HR 0.84;95%CI 0.67-1.05;调整HR 0.89;95%CI 0.41-1.94)。
- 负荷试验结果中仅严重异常具有预后意义(HR 1.45;95%CI 1.10-1.91)。
临床怎么用
- 对于疑似冠心病稳定症状患者,初始选择CTA或负荷试验均可,两者长期死亡率相似。
- CTA提示任何程度异常(包括轻度非阻塞性CAD)应视为死亡风险升高的预后标志。
- 负荷试验仅严重异常结果具有预后意义,轻度异常预后价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Symptoms suggestive of coronary artery disease (CAD) often require noninvasive testing for diagnostic and prognostic evaluation. OBJECTIVE: To determine long-term outcomes in patients randomized to functional (stress) vs anatomic (coronary computed tomographic angiography [CTA]) initial testing. DESIGN, SETTING, AND PARTICIPANTS: This study is a 2025 follow-up analysis of mortality of participants in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) randomized clinical trial, which was conducted from 2009 to 2014, using a 2024 National Death Index search. Median (IQR) follow-up duration was 10.6 (9.9-11.3) years; maximum follow-up was 12.4 years. PROMISE was conducted at 193 multispecialty outpatient sites in North America among 10 003 symptomatic patients requiring testing for suspected CAD. Data analysis was conducted from August 2024 to March 2025. INTERVENTION: Participants were randomized 1:1 to initial CTA or stress testing. Testing and subsequent care were performed by sites according to usual practices. MAIN OUTCOMES AND MEASURES: The PROMISE trial's original primary end point was death, myocardial infarction, unstable angina hospitalization, or major procedural complication. The primary end point for extended follow-up was all-cause death, with cardiovascular (CV) death as a secondary end point. RESULTS: At enrollment, mean (SD) participant age was 61 (8) years, 5270 participants (52.7%) were women, and 8762 (87.6%) had chest pain or dyspnea. Death occurred in 1128 participants (14.4%), including 558 (14.3%) in the CTA arm and 570 (14.5%) in the stress arm (unadjusted hazard ratio [HR], 0.98; 95% CI, 0.87-1.10). There was no demonstrable difference in cardiovascular mortality, although the point estimate favored CTA (HR, 0.84; 95% CI, 0.67-1.05; adjusted HR, 0.89; 95% CI, 0.41-1.94). There were no significant interactions between all-cause death or CV death and study arm by age (<60 or ≥60 years) (P value for interaction = .19), gender (P value for interaction = .60), or race and ethnicity (P value for interaction = .47). A CTA indicating any degree of abnormality, including mild (nonobstructive CAD), moderate, and severe findings, conferred elevated adjusted HRs of death (1.99-3.44; all P < .001) compared to normal study results. Among stress testing results, only a severe abnormality was prognostically significant (HR, 1.45; 95% CI, 1.10-1.91). In landmark analyses of those alive at 90 days, there were no interactions between randomized testing and use of statins (P value for interaction = .22), β-blockers (P value for interaction = .76), or antiplatelet agents (P value for interaction = .49). CONCLUSIONS AND RELEVANCE: In long-term follow-up of the PROMISE randomized clinical trial, initial noninvasive test selection in patients with stable symptoms of suspected CAD did not affect all-cause or CV mortality at 10 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01174550.
引用
- Douglas PS, Stebbins A, Foldyna B, et al. Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease: Long-Term Follow-Up of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40864459. doi:10.1001/jamacardio.2025.2882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。